Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Satralizumab
Satralizumab is a lab-made antibody that helps prevent relapses in neuromyelitis optica, a rare autoimmune condition affecting the optic nerves and spinal cord.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Rigshospitalet
Klinik for Hjerne- og Nervesygdomme hos Børn og Unge 5004N
Copenhagen, Denmark
IRCCS Istituto Giannina Gaslini
U.O.S.D. Centro di Miologia Traslazionale e Sperimentale
Genoa, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
U.O.C. Neuropsichiatria Infantile - Unità Trials
La Massimina-Casal Lumbroso, Italy

Sponsor: F. Hoffmann-La Roche AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.